| Ms Erica Querze, LPC | |
|
1 Golden Hill, Milford, CT 06460 | |
| (203) 804-9881 | |
| Not Available |
| Full Name | Ms Erica Querze |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 1 Golden Hill, Milford, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184113730 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Erica Querze, LPC 50 Commerce Park, Milford, CT 06460 Ph: (203) 804-9881 | Ms Erica Querze, LPC 1 Golden Hill, Milford, CT 06460 Ph: (203) 804-9881 |
News Archive
Callidus Software Inc., the leader in Sales Performance Management (SPM), today announced that Blue Cross Blue Shield of North Carolina (BCBSNC), has selected the Callidus Monaco Suite to manage sales performance and incentive compensation programs. Under the enterprise class SaaS agreement, signed in the third quarter of 2009, BCBSNC will use the Callidus Monaco Suite for its 4,000 brokers.
Findings from a new study examining human and canine brain cancer cells suggest that cannabidiol could be a useful therapy for a difficult-to-treat brain cancer. Cannabidiol, or CBD, is a non-psychoactive chemical compound derived from marijuana.
"In recent years, Kyrgyzstan has benefited from a significant increase in international funding to improve health care," but, "[d]espite this influx of international funding, many people in Kyrgyzstan are unable to get the lifesaving medicines that they need," Madina Tokombaeva, director of the Harm Reduction Network (HRN) in Kyrgyzstan, and Maryam Beishenova, program coordinator at HRN, write in this Open Society Foundations blog post.
Low- and middle-income countries in remote locations with little access to care can create sustainable neurosurgical programs by recruiting and training young, local doctors, according to a Rutgers study.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.
› Verified 9 days ago
Lamont Dixon, Counselor Medicare: Not Enrolled in Medicare Practice Location: 949 Bridgeport Ave, Milford, CT 06460 Phone: 203-878-6365 | |
Berthania Boursiquot, LPCA Counselor Medicare: Not Enrolled in Medicare Practice Location: 949 Bridgeport Ave, Milford, CT 06460 Phone: 203-878-6365 Fax: 203-301-2397 | |
Ewa Kluk, Counselor Medicare: Not Enrolled in Medicare Practice Location: 326 W Main St Ste 205, Milford, CT 06460 Phone: 203-296-3002 | |
Sheila M. Sneed, LADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 203 High St, Milford, CT 06460 Phone: 203-874-6270 | |
Joanne C Prete, ATR, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 4 Oxford Rd Ste C1, Milford, CT 06460 Phone: 203-600-8900 | |
Douglas William Roberto, DARC, RCP Counselor Medicare: Not Enrolled in Medicare Practice Location: 14 Village Rd, Milford, CT 06460 Phone: 203-843-4143 | |
Margaret Burton, Counselor Medicare: Not Enrolled in Medicare Practice Location: 580 Naugatuck Ave, Milford, CT 06461 Phone: 475-331-2100 |